Value Partners Investments Inc. Raises Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Value Partners Investments Inc. lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 35.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,033 shares of the medical research company's stock after purchasing an additional 1,837 shares during the quarter. Value Partners Investments Inc.'s holdings in Thermo Fisher Scientific were worth $3,502,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of TMO. Bernard Wealth Management Corp. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $25,000. Pillar Financial Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $30,000. Noble Wealth Management PBC purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $35,000. Finally, Cassady Schiller Wealth Management LLC grew its stake in Thermo Fisher Scientific by 89.2% in the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock valued at $36,000 after purchasing an additional 33 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

TMO traded up $1.37 during trading on Thursday, reaching $412.02. The company's stock had a trading volume of 2,926,073 shares, compared to its average volume of 1,955,518. The firm has a fifty day simple moving average of $410.39 and a two-hundred day simple moving average of $485.33. The company has a market cap of $155.53 billion, a price-to-earnings ratio of 24.17, a PEG ratio of 2.13 and a beta of 0.78. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same period in the prior year, the firm posted $5.11 earnings per share. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TMO. Robert W. Baird dropped their target price on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Barclays decreased their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research report on Tuesday. Evercore ISI cut their target price on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Scotiabank dropped their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. Finally, Argus reduced their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $604.05.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.